Take Long View

What: Shares of Merit Medical Systems (NASDAQ:MMSI), a manufacturer of disposable medical devices used in primarily in cardiology, radiology and endoscopy, were in the doghouse in early trading today. The stock was down more than 20% at one point this morning after the company reported its third quarter results.

So what: Merit reported revenue during the third quarter of $136 million, which was up 6% over the year-ago period. Non-GAAP net income came in at $8.9 million which translated into $0.20 in earnings-per-share, which was down from the $0.25 EPS that it reported in the year-ago period. Although revenue grew during the quarter, lower gross margins mixed with higher spending company-wide appear to be the main causes of the earnings decline.

While the $0.20 in earnings-per-share managed to match analyst projections, revenue came in lighter than the $137.8 million that they were expecting, which is likely the cause of the sell-off today.

Now what: During the quarter, the company opened up a new facility in Tijuana, Mexico that appears to have temporarily put pressure on its gross margins, but the company believes that as more production is moved to its new facility its gross margins will eventually rise. In addition, the company reported that it received the CE mark (an important European conformity designation) for its Centros and CentrosFLO Long-Term Hemodialysis Catheters, and sales of these products jumped more than 76% during the period. Both of these developments could are certainly positive signs for the company and could lead to higher earnings in the coming quarters.

Despite the huge sell-off today, shares of Merit are still up more than 10% year to date and nearly 50% over the last year, so perhaps a pull-back shouldn't come as such a surprise. If the company is able to meet or exceed the 15% growth rate that analysts are projecting over the coming 5 years, then long-term investors in this company should do just fine.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.